ClinicalTrials.gg
Active, not recruitingNCT01000350Updated Oct 16, 2026

Intravenous (IV) Saline and Exercise in Postural Tachycardia Syndrome (POTS)

An interventional study of Saline and Placebo in Postural Tachycardia Syndrome, sponsored by Vanderbilt University Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Vanderbilt University Medical Center · Not applicable, Interventional, and Treatment

How we know

Updated Oct 16, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Postural Orthostatic Tachycardia Syndrome by Vanderbilt University Medical Center — 2 open to participants now, 13 under way, none of them phase 3. Postural Orthostatic Tachycardia Syndrome · Vanderbilt University Medical Center.

Planned enrollment
7th of 13
40 · median 40
Started
2009
with 1 other
No phase
5 of 18
none open now
Primary completion
2031-06
later than 12 of 12 live
Registered
2nd of 18
by date

Among the 18 studies in Postural Orthostatic Tachycardia Syndrome by Vanderbilt University Medical Center, this one is the 7th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2009, is one of 5 with no phase, reaches primary completion later than 12 of the 12 other live ones, and was the 2nd registered.

Postural Orthostatic Tachycardia Syndrome

136 studies on the registry are indexed under Postural Orthostatic Tachycardia Syndrome; 42 are open to participants now.

Browse Postural Orthostatic Tachycardia Syndrome studies →

Open to participants now

2 of the 18 studies in Postural Orthostatic Tachycardia Syndrome by Vanderbilt University Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 29 Postural Orthostatic Tachycardia Syndrome studies recruiting now, 9 (31%) set no upper age limit and 16 (55%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Postural Orthostatic Tachycardia Syndrome by Vanderbilt University Medical Center, or all of them as a file.
02

Study summary

The investigators will test whether an intravenous infusion of saline (salt water) will improve the exercise capacity in patients with postural tachycardia syndrome (POTS).

03

Conditions studied

  • Postural Tachycardia Syndrome

Keywords

  • orthostatic intolerance
  • exercise capacity
  • tachycardia
  • POTS
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet diagnostic criteria of Postural Tachycardia Syndrome (POTS) 28
  • Age between 18-65 years
  • Male and female are eligible (although the majority of POTS patients are female).
  • Able and willing to provide

Exclusion criteria

Exclusion Criteria:

  • Presence of medical conditions that can explain postural tachycardia (e.g., acute dehydration, medications)
  • Pregnancy
  • Other factors which in the investigator's opinion would prevent the subject from completing the protocol.
  • Patients who are bedridden or chair-ridden
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Exercise Post Saline

    Saline infusion 1L hours before exercise test

    Drug: Saline

  • Placebo comparator
    Placebo

    Placebo given prior to exercise test

    Other: Placebo

Interventions

  • DrugSaline SolutionStudies of Saline SolutionSaline Solution pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    IV Normal Saline infused over 30-60 minutes given 3-6 hours PRIOR to exercise study

    Also known as: Normal Saline, 0.9% saline

  • OtherPlacebo

    Placebo x1 lactose tablet

06

What researchers measure

Primary outcomes

  1. Difference in VO2max between saline day and placebo day

    VO2max will be measured hours after saline and after placebo. The 2 interventions will be less than 2 weeks apart.

    Time frame: Within 2 week

Secondary outcomes

  1. Exercise capacity/Maximal Load (Watts) during peak VO2

    Maximal exercise load will be measured hours after saline and after placebo. The 2 interventions will be less than 2 weeks apart.

    Time frame: Less than 2 weeks

  2. Cardiac output between exercise tests (inert gas rebreathing technique)

    Time frame: 2-10 Days between exercise tests

07

Study locations

1 site
08

References and documents

Publications

  • Raj SR, Biaggioni I, Yamhure PC, Black BK, Paranjape SY, Byrne DW, Robertson D. Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome. Circulation. 2005 Apr 5;111(13):1574-82. doi: 10.1161/01.CIR.0000160356.97313.5D. Epub 2005 Mar 21. PubMed 15781744 ↗
09

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimatedDate before it movedWhere the date was before it moved

The record gives a start of Oct 2009, a primary completion of Jun 2031 and a completion of Jun 2031. It does not say whether these dates are actual or estimated.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Jun 2028 → Jun 2031 and completion Jun 2028 → Jun 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2009
First posted
Oct 23, 2009
Start
Oct 2009
Primary completionEst.
Jun 2031was Jun 2028
CompletionEst.
Jun 2031was Jun 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2028→Jun 2031
Oct 16, 2026
Study completion
Jun 2028→Jun 2031
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Primary completion Jun 2028→Jun 2031
    Study completion Jun 2028→Jun 2031
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01000350
Responsible party
Satish R. Raj (Adjunct Associate Professor of Medicine, Vanderbilt University Medical Center) — Principal investigator
First posted
Oct 23, 2009
Start date
Oct 2009
Primary completion
Jun 2031 (estimated)
Completion
Jun 2031 (estimated)
Last update
Oct 16, 2026

Study contacts

Satish R Raj, MD MSCI
principal investigator · Vanderbilt University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Saline Solution

Start the discussion